SG11201605501RA - A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc) - Google Patents

A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc)

Info

Publication number
SG11201605501RA
SG11201605501RA SG11201605501RA SG11201605501RA SG11201605501RA SG 11201605501R A SG11201605501R A SG 11201605501RA SG 11201605501R A SG11201605501R A SG 11201605501RA SG 11201605501R A SG11201605501R A SG 11201605501RA SG 11201605501R A SG11201605501R A SG 11201605501RA
Authority
SG
Singapore
Prior art keywords
rcc
dihydro
oxo
treatment
cell carcinoma
Prior art date
Application number
SG11201605501RA
Inventor
Friedhelm Bladt
Manja Friese-Hamim
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG11201605501RA publication Critical patent/SG11201605501RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201605501RA 2014-01-07 2014-12-16 A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc) SG11201605501RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14000036 2014-01-07
PCT/EP2014/003365 WO2015104042A1 (en) 2014-01-07 2014-12-16 A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc)

Publications (1)

Publication Number Publication Date
SG11201605501RA true SG11201605501RA (en) 2016-08-30

Family

ID=49916969

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201605501RA SG11201605501RA (en) 2014-01-07 2014-12-16 A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc)

Country Status (17)

Country Link
US (1) US20160331748A1 (en)
EP (1) EP3091980A1 (en)
JP (1) JP2017502978A (en)
KR (1) KR20160099724A (en)
CN (1) CN105873591A (en)
AR (1) AR099035A1 (en)
AU (1) AU2014377079A1 (en)
CA (1) CA2935889C (en)
CL (1) CL2016001726A1 (en)
IL (1) IL246628A0 (en)
MX (1) MX2016008815A (en)
MY (1) MY191613A (en)
PH (1) PH12016500964A1 (en)
RU (1) RU2016132401A (en)
SG (1) SG11201605501RA (en)
TW (1) TW201609103A (en)
WO (1) WO2015104042A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3996688T3 (en) * 2019-07-10 2023-11-30 Merck Patent Gmbh Pharmaceutical preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007032507A1 (en) * 2007-07-12 2009-04-02 Merck Patent Gmbh pyridazinone derivatives
AU2009336839B2 (en) * 2009-01-08 2015-12-24 Merck Patent Gmbh Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

Also Published As

Publication number Publication date
CA2935889C (en) 2022-08-16
WO2015104042A1 (en) 2015-07-16
CL2016001726A1 (en) 2016-12-16
JP2017502978A (en) 2017-01-26
AR099035A1 (en) 2016-06-22
IL246628A0 (en) 2016-08-31
CA2935889A1 (en) 2015-07-16
RU2016132401A3 (en) 2018-08-29
MX2016008815A (en) 2016-09-08
AU2014377079A1 (en) 2016-08-18
NZ722879A (en) 2021-08-27
TW201609103A (en) 2016-03-16
US20160331748A1 (en) 2016-11-17
CN105873591A (en) 2016-08-17
RU2016132401A (en) 2018-02-13
MY191613A (en) 2022-07-03
EP3091980A1 (en) 2016-11-16
KR20160099724A (en) 2016-08-22
PH12016500964A1 (en) 2016-06-20

Similar Documents

Publication Publication Date Title
IL283740A (en) Cartridge for an aerosol-generating system
IL276463B (en) Pyridazinone herbicides
HK1223100A1 (en) Heterocyclic compounds
GB2552084B (en) A locker system
SG11201704562YA (en) Heating apparatus for a smoke-free cigarette
HK1211390A1 (en) Bypass path loss reduction
ZA201700302B (en) Halogen-substituted compounds
GB201401910D0 (en) A locker system
GB201416742D0 (en) A locker system
IL248766B (en) Method for treating renal cell carcinoma
AU358772S (en) Stirrup
HRP20180637T1 (en) Connection system for a sliding board
GB201411043D0 (en) A locker system
HK1211869A1 (en) A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc) (hcc) 6--16--
SG11201605501RA (en) A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc)
SG11201700276QA (en) Quinoxaline compounds, method for preparing the same and use thereof
GB2527638B (en) Bypass path loss reduction
GB2524135B (en) A locker system
GB201420970D0 (en) eGURE, egure, Egure
GB201418676D0 (en) Compounds for use
GB201416641D0 (en) A locker system
GB201409792D0 (en) Compounds for use